A team of scientists has discovered that a single alteration in the genetic code of about a fourth of African-Americans helps protect them from coronary artery disease, the leading cause of death in Americans of all races.
An antibiotic known for immunosuppression could also point the way to the development of new anti-cancer agents, researchers have reported. Tautomycetin targets an enzyme which plays an important role in cell activities such as proliferation and differentiation.
Mylan Inc. said it acquired a license to make and sell a generic version of a potential HIV drug in sub-Saharan Africa, India, and some developing countries.
Eli Lilly and Co.'s fourth-quarter net income jumped 28 percent on sales from established drugs, but it expects earnings to slide this year as it faces generic competition and health care overhaul costs.
Drugmaker Mylan Inc. said the Food and Drug Administration has approved four dose amounts of its generic version of Shionogi Pharma's Sular tablets for treating hypertension.
GlaxoSmithKline Plc. said the Food and Drug Administration is asking the company for more information before approving the drug Avodart for men at risk of getting prostate cancer.
Major drugmakers are reporting fourth-quarter earnings ranging from modestly better to bleak, but they're all showing dents from the macroeconomic forces that constrain the industry, now and for the foreseeable future.
French drugmaker Sanofi-Aventis SA said a clinical trial showed its drug candidate iniparib did not improve survival or slow disease progression in patients with breast cancer.
Micronic Europe has announced a new 1.4ml amber polypropylene storage tube that, used in conjunction with a secure screw cap, ensures the integrity of light sensitive biological samples even over long-term storage periods.
Tecan has launched a new 25 ml trough designed to reduce waste of valuable reagents in automated liquid handling applications. These troughs have a conical base design to minimize the inaccessible liquid volume.
Massachusetts General Hospital investigators have developed a novel system for delivery of growth factors to chronic wounds such as pressure sores and diabetic foot ulcers.
An innovative genetic strategy for rendering T-cells resistant to HIV infection without affecting their normal growth and activity is described in a newly published paper.
BioFocus announced that a subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck’s liquid chemical library collection.
Cetero Research has conducted its milestone 20,000th early-phase clinical study. This achievement highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology, and generic clients.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.